ClinicalTrials.gg
Not yet recruitingNCT07352176Updated Jan 20, 2026

Study on the Effectiveness and Safety of CLE Combined With Cryobiopsy for Diagnosis of Pulmonary Lesions

An interventional study of Confocal laser endomicroscopy combined cryobiopsy and Conventional cryobiopsy in Pulmonary Lesion and Lung Cancer, sponsored by Guangzhou Medical University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-20.

Sponsored by Guangzhou Medical University · Not applicable, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 850 studies in Lung Neoplasms with a site in China — 376 open to participants now, 423 under way, 34 of them phase 3. Lung Neoplasms · China.

Planned enrollment
427th of 590
40 · median 90
Started
2026
with 91 others
No phase
214 of 850
93 open now
Primary completion
2026-12
later than 187 of 422 live
Registered
747th of 850
by date

Among the 850 studies in Lung Neoplasms with a site in China, this one is the 427th largest by planned enrollment of the 590 interventional ones that give a count, is one of 92 that started in 2026, is one of 214 with no phase, reaches primary completion later than 187 of the 422 other live ones, and was the 747th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

376 of the 850 studies in Lung Neoplasms with a site in China are open now. Recruiting first, the newest first:

371 more — sign in →

All 376 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 850 studies in Lung Neoplasms with a site in China, or all of them as a file.
02

Study summary

Forty subjects meeting the inclusion and exclusion criteria were recruited at a single center and signed informed consent forms. Among them, 20 patients in the diffuse group and 20 patients in the localized group were randomly assigned to the conventional radial endobronchial ultrasound combined with cryobiopsy group (conventional group) and the confocal laser endomicroscopy combined with cryobiopsy group (combined group). During the operation, the operator manipulated the bronchoscope to reach the lesion. After confirming the arrival at the lesion using radial endobronchial ultrasound/confocal laser endomicroscopy, cryobiopsy was performed, and the size of the sample was recorded. CBCT scanning was conducted after cryobiopsy. If there was no hole-in-lesion image, cryobiopsy was performed again under CBCT guidance. CBCT scanning was performed after biopsy to determine whether there were any adverse events.

03

Conditions studied

  • Pulmonary Lesion
  • Lung Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients over 18 years old with lung lesions indicated by chest CT;
  2. Preoperative CT indicates that the lung lesion to be biopsied has a bronchus leading to it;
  3. Able to understand and voluntarily sign the written form. -

Exclusion criteria

Exclusion Criteria:

  1. Patients with to anesthesia or bronchoscopy;
  2. Patients with uncorrectable coagulation disorders;
  3. Patients who cannot discontinue therapeutic anticoagulants within an appropriate time interval before surgery;
  4. Patients with severe liver or kidney dysfunction, mental illness, etc.;
  5. Pregnant or lactating patients;
  6. Patients without a clear histological or clinical diagnosis;
  7. Subjects deemed unsuitable for participation in this study by the investigator.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    Diffuse- Conventional Group

    The Diffuse-Conventional Group used conventional cryobiopsy for lung lesions.

    Other: Conventional cryobiopsy

  • Experimental
    Diffuse- Combined Group

    The Diffuse-Combined Group used CLE combined with cryobiopsy for lung lesions

    Other: Confocal laser endomicroscopy combined cryobiopsy

  • Active comparator
    Localized - Convention Group

    The Localized-Conventional Group used conventional cryobiopsy for lung lesions.

    Other: Conventional cryobiopsy

  • Experimental
    Localized - Combined Group

    The Localized-Combined Group used CLE combined with cryobiopsy for lung lesions

    Other: Confocal laser endomicroscopy combined cryobiopsy

Interventions

  • OtherConfocal laser endomicroscopy combined cryobiopsy

    Patients in the combined group will undergo CLT combined with cryobiopsy for lung lesions.

  • OtherConventional cryobiopsy

    Patients in the conventional group will underg cryobiopsy for lung lesions.

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events

    The Incidence of adverse events = (the number of adverse event / the number of procedures) \* 100%

    Time frame: 7 days after procedure

Secondary outcomes

  1. Diagnostic yield

    The diagnostic yield = (the number of successful diagnoses / the number of completed biopsies) \* 100%

    Time frame: Immediately after the procedure

  2. Hole-in-lesion rate

    The rate of "hole-in-lesion" = (The number of cases with "hole-in-lesion" / The total number of cases that completed biopsy) \* 100% The definition of "Hole-in-lesion": After cryobiopsy, a CBCT scan is performed, and the CBCT image shows the presence of a cavity within the lesion.

    Time frame: During the procedure

07

Study locations

1 site
08

References and documents

Publications

  • Kramer T, Wijmans L, de Bruin M, van Leeuwen T, Radonic T, Bonta P, Annema JT. Bronchoscopic needle-based confocal laser endomicroscopy (nCLE) as a real-time detection tool for peripheral lung cancer. Thorax. 2022 Apr;77(4):370-377. doi: 10.1136/thoraxjnl-2021-216885. Epub 2021 Jun 25. PubMed 34172559 ↗
  • Wellikoff AS, Holladay RC, Downie GH, Chaudoir CS, Brandi L, Turbat-Herrera EA. Comparison of in vivo probe-based confocal laser endomicroscopy with histopathology in lung cancer: A move toward optical biopsy. Respirology. 2015 Aug;20(6):967-74. doi: 10.1111/resp.12578. Epub 2015 Jun 19. PubMed 26094505 ↗
  • Sorokina A, Danilevskaya O, Averyanov A, Zabozlaev F, Sazonov D, Yarmus L, Lee HJ. Comparative study of ex vivo probe-based confocal laser endomicroscopy and light microscopy in lung cancer diagnostics. Respirology. 2014 Aug;19(6):907-13. doi: 10.1111/resp.12326. Epub 2014 Jun 9. PubMed 24909555 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2026; primary completion for Dec 2026, 10 months later.

Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 10 months is below that.

Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2026
First posted
Jan 20, 2026
StartEst.
Feb 1, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jan 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07352176
Lead sponsor
Guangzhou Medical University
Responsible party
Li Shiyue (professor, Guangzhou Medical University) — Principal investigator
First posted
Jan 20, 2026
Start date
Feb 1, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jan 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion